Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 3/20 | 0.37 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL262959 | 0.85 | TSHR (0.38) | ALDH1A1KDM4EHPGDGAAKMT2A | |
| SCHEMBL2703593 | 0.84 | KLKB1 (0.33) | KLKB1ALDH1A1KMT2ANPC1DGAT1 | |
| SCHEMBL31472241 | 0.83 | GABRP (0.34) | KLKB1ALDH1A1KDM4EHPGDKMT2A | |
| SCHEMBL25193532 | 0.81 | DGAT1 (0.38) | KLKB1GAADGAT1 | |
| SCHEMBL18131171 | 0.80 | L3MBTL1 (0.32) | KLKB1ALDH1A1KMT2AL3MBTL1NPC1 | |
| SCHEMBL6470056 | 0.80 | KMT2A (0.49) | KLKB1ALDH1A1KDM4EHPGDKMT2A | |
| SCHEMBL21858181 | 0.80 | DGAT1 (0.35) | KLKB1NPC1DGAT1 | |
| SCHEMBL24537124 | 0.79 | PTGER1 (0.39) | KLKB1KDM4EHPGDKMT2ANPC1 | |
| SCHEMBL28571743 | 0.78 | KLKB1 (0.34) | KLKB1DGAT1 | |
| SCHEMBL26928849 | 0.78 | L3MBTL1 (0.37) | KLKB1ALDH1A1L3MBTL1NPC1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2183241-B1 | 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | PFIZER LTD (GB) | 2012-12-19 | — | — | EP | disclosed |
| US-8134007-B2 | Pyridine derivatives | PFIZER INC. (US) | 2012-03-13 | — | — | US | disclosed |
| EP-2183241-A2 | 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | Pfizer Limited (GB) | 2010-05-12 | — | — | EP | disclosed |
| US-20090048306-A1 | PYRIDINE DERIVATIVES | PFIZER, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2008135826-A2 | 2 -PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | PFIZER LIMITED (GB) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048306-A1 | PYRIDINE DERIVATIVES | SDHA, P2RX4, P2RX3 | KLKB1 2661/4885ALKBH1 3552/4885ALDH1A1 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.